Saratov JOURNAL of Medical and Scientific Research

Features of clinical and laboratory manifestations of COVID-19 in outpatients one month after their recovery

Year: 2021, volume 17 Issue: №3 Pages: 587-593
Heading: Тhematic supplement Article type: Original article
Authors: Tyapkina D.A., Boroday А.А., Tyapayeva A.R., Semenova O.N., Naumova E.A.
Organization: Saratov State Medical University

Objective: to identify in patients with cardiovascular diseases (CVD), who underwent COVID-19, dynamic changes in clinical, laboratory and psychological manifestations of the disease one month after their recovery. Material and Methods. A survey was conducted among 54 CVD outpatients with confirmed COVID-19. One month after their recovery, the following was carried out: a survey about the persisting clinical manifestations; physical examination; laboratory and instrumental diagnostics; testing according to the HADS scale and the Beck scale. 34 patients agreed. Results. People aged 45-82 years were most often ill. A month after treatment, there is a decrease in the number of patients with symptoms of respiratory system damage, but symptoms of damage to other systems persist: 41.2% — destabilization of blood pressure, 52.9% — sleep disorders, 58.8% — memory loss, 94.1 % — decreased exercise tolerance. When assessing the mental properties of a person, it was found that 29.4% of respondents have subclinical and clinically severe depression. Conclusion. Within one month after treatment, there are fewer patients with cough, shortness of breath, congestion and chest pain, but they still have manifestations from the nervous and cardiovascular systems. Some individuals, after recovery, developed new symptoms: shortness of breath on exertion or at rest, swelling of the lower extremities, tachycardia, hair loss, unsteadiness or "unsteadiness" when walking.

1. Sizova EN, Shmakova LN, Vidyakina EV. Medical ecology of SARS-CoV-2 (literature review). Vyatka Medical Bulletin 2020; 3 (67): 98-103.
2. Ivannikov АА, Esaulenko AN, Vasilchenko МК, et al. COVID-19 and cardiovascular system. Part II: Post-COVID syndrome. Emergency Medical Care: Russian Sklifosovsky Journal 2021; 10 (2): 248-58.
3. Vaes AW, Goertz YMJ, Van Herck M, et al. Recovery from COVID-19: a sprint or marathon?: 6-month follow-up data from online long COVID-19 support group members. ERJ Open Res 2021; 7 (2): 00141 -2021. DOI: 10.1183/23120541.00141 -2021.
4. Recommendations for the management of patients with COVID-19 coronavirus infection on an outpatient basis in the acute phase and with post-COVID syndrome [Electronic resource]. URL: link is active on 27.09.2021.
5. Zhou Y, Chi J, Lv W, et al. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (COVID-19). Diabetes Metab Res Rev 2021; 37 (2): e3377. DOI: 10.1002/dmrr. 3377.
6. Konradi АО, Villevalde SV, Duplyakov DV, et al. An open-label multicenter observational study (registry) of patients recovered from coronavirus disease 2019 (COVID-19) with involvement of the cardiovascular system or with baseline severe cardiovascular diseases: rationale, design, and implications for clinical practice. Russian Journal of Cardiology 2021; 26 (1): 99-104.
7. Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain 2020; 143 (10): 3104-20. DOI: 10.1093/brain/awaa240.
8. Shepeleva II, Chernysheva AA, Kiryanova EM, et al. The nervous system damages and psychological and psychiatric complications on the COVID-19 pandemic. Social and Clinical Psychiatry 2020; 30 (4): 76-82.
9. Perez СА. Looking ahead: The risk of neurologic complications due to COVID-19. Neurol Clin Pract 2020; 10 (4): 371-4. DOI: 10.1212/CPJ. 0000000000000836.
10. Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 2020; 87:18-22. DOI: 10.1016/j.bbi. 2020.03.031.
11. Oronsky B, Larson C, Hammond TC, et al. A Review of Persistent Post-COVID Syndrome (PPCS). Clin Rev Allergy Immunol 2021; 20: 1-9. DOI: 10.1007/s12016-021-08848-3.

2021_03-1_587-593.pdf349.41 KB

No votes yet